Novo Nordisk A/S Common Stock (NVO)

Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.

Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.

Investors dumped technology stocks as they move to safer assets like Gold and Silver that rose today.

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

This could finally be the start of the drugmaker's comeback.

Novo Nordisk's weight loss pill could give the company's numbers a big boost this year.

CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk.

The target action date for orforglipron is now April 10.

Both companies are trading at attractive valuations today.

The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate.

Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.

There might be massive upside ahead for these drugmakers.

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Both companies may succeed in this industry.

This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning.

It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.

The company got some bad news to start 2026.

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]

This biotech has candidates in late-stage clinical development.

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally underscores the company's status as the undisputed titan of the large-cap healthcare sector, a position bolstered by

Wall Street witnessed a surge in risk-on sentiment today as the Cboe Volatility Index (VIX) fell by over 5%, closing at 15.94. The decline marks a sharp reversal from the "Greenland Chill" that gripped markets earlier this week, providing a clear signal that investors are betting on a stabilization